Table 2 Clinical characteristics of the Ologen-augmented (Phaco-Oloxen) and non-augmented (PhacoXen) groups in combined Xen gel stent implantation and phacoemulsification

Age, years (mean ± SD)

65.53 ± 7.78

70.66 ± 7.20

0.164*

Gender, n, male:female (%)

10:9 (52.6%:47.4%)

6:6 (50.0%:50.0%)

0.886^†

Laterality, n, OD:OS (%)

11:8 (57.9%:42.1%)

6:6 (50.0%:50.0%)

0.667^†

HTN, n, yes:no (%)

6:13 (33.3%:66.7%)

6:6 (50.0%:50.0%)

0.452^

DM, n, yes:no (%)

3:16 (15.8%:84.2%)

3:9 (25.0%:75.0%)

0.653^

Preoperative visual acuity, logMAR (mean ± SD)

0.50 ± 0.47

0.30 ± 0.35

0.120*

Preoperative intraocular pressure, mmHg (mean ± SD)

18.05 ± 6.95

15.42 ± 5.65

0.306*

Prior glaucoma surgery, n yes:no (%)

1:17 (5.3%:94.7%)

0:12(0%:100%)

0.427^

Number of preoperative medications, n (mean ± SD)

3.57 ± 0.69

3.08 ± 0.79

0.101*

Preoperative diagnosis, n (%)

0.106^†

Primary open-angle glaucoma

12 (63.2%)

4 (33.3%)

Secondary open-angle glaucoma

7 (36.8%)

8 (66.7%)

CCT, (mean ± SD)

528.84 ± 40.48

524.97 ± 42.50

0.683*

ECD, (mean ± SD)

2522.86 ± 384.39

2632.77 ± 353.25

0.367*

Axial length, mm, (mean ± SD)

23.75 ± 1.18

23.32 ± 1.69

0.646*

RNFL thickness, (mean ± SD)

65.21 ± 13.25

64.20 ± 10.51

0.872*

VFI, (mean ± SD)

40.47 ± 36.30

62.50 ± 34.46

0.243*

MD, (mean ± SD)

-20.37 ± 11.12

-13.30 ± 9.88

0.155*

PSD, (mean ± SD)

6.63 ± 3.84

6.29 ± 2.40

0.980*